IL207182A - Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids - Google Patents

Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids

Info

Publication number
IL207182A
IL207182A IL207182A IL20718210A IL207182A IL 207182 A IL207182 A IL 207182A IL 207182 A IL207182 A IL 207182A IL 20718210 A IL20718210 A IL 20718210A IL 207182 A IL207182 A IL 207182A
Authority
IL
Israel
Prior art keywords
norpregna
11beta
17alpha
acetoxy
dione
Prior art date
Application number
IL207182A
Other languages
English (en)
Hebrew (he)
Other versions
IL207182A0 (en
Original Assignee
Us Health
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health, Hra Pharma Lab filed Critical Us Health
Publication of IL207182A0 publication Critical patent/IL207182A0/en
Publication of IL207182A publication Critical patent/IL207182A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
IL207182A 2008-01-29 2010-07-25 Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids IL207182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (2)

Publication Number Publication Date
IL207182A0 IL207182A0 (en) 2010-12-30
IL207182A true IL207182A (en) 2015-06-30

Family

ID=40551565

Family Applications (2)

Application Number Title Priority Date Filing Date
IL207182A IL207182A (en) 2008-01-29 2010-07-25 Use of 17 alpha-acetoxy-11 beta- (4– n, n– dimethylamino phenyl) –19 – norfergana – 4, 9 – dian – 3, 20 – deion (Olipristal acetate) for the preparation of a drug to lower or stop bleeding in patients suffering from uterine fibroids
IL234149A IL234149B (en) 2008-01-29 2014-08-17 Use of an effective amount of 17-acetoxy-11-[4-n, n-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof for the manufacture of a medicament for treating or preventing leiomyomatosis or metastatic leiomyoma in a patient

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL234149A IL234149B (en) 2008-01-29 2014-08-17 Use of an effective amount of 17-acetoxy-11-[4-n, n-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof for the manufacture of a medicament for treating or preventing leiomyomatosis or metastatic leiomyoma in a patient

Country Status (20)

Country Link
US (5) US8299050B2 (cg-RX-API-DMAC10.html)
EP (2) EP2252301B1 (cg-RX-API-DMAC10.html)
JP (2) JP5906016B2 (cg-RX-API-DMAC10.html)
KR (2) KR101571400B1 (cg-RX-API-DMAC10.html)
AU (1) AU2009209652B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907028B8 (cg-RX-API-DMAC10.html)
CA (2) CA2857798A1 (cg-RX-API-DMAC10.html)
CY (1) CY1116485T1 (cg-RX-API-DMAC10.html)
DK (1) DK2252301T3 (cg-RX-API-DMAC10.html)
ES (1) ES2450592T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20140132T1 (cg-RX-API-DMAC10.html)
IL (2) IL207182A (cg-RX-API-DMAC10.html)
MX (1) MX2010008270A (cg-RX-API-DMAC10.html)
NZ (1) NZ587439A (cg-RX-API-DMAC10.html)
PL (1) PL2252301T3 (cg-RX-API-DMAC10.html)
PT (1) PT2252301E (cg-RX-API-DMAC10.html)
SI (1) SI2252301T1 (cg-RX-API-DMAC10.html)
TW (1) TWI445537B (cg-RX-API-DMAC10.html)
WO (1) WO2009095418A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201006049B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
JP6200493B2 (ja) * 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
US20150320766A1 (en) * 2012-12-14 2015-11-12 Laboratoire Hra-Pharma Copper intrauterine device
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
KR20150139919A (ko) * 2013-04-10 2015-12-14 쁘레글렘 에스아 자궁 섬유종의 치료에서 사용하기 위한 프로게스테론 수용체 조절제
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
US10238722B2 (en) 2014-11-24 2019-03-26 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
WO2021166001A1 (en) 2020-02-19 2021-08-26 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ATE235907T1 (de) 1995-02-02 2003-04-15 Schering Ag Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
ES2152671T3 (es) 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
AU747710B2 (en) 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20090149434A1 (en) 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
JP2010514793A (ja) 2006-12-28 2010-05-06 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンのバイオアベイラビリティを改善するための方法および製剤
SI2148681T1 (sl) * 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
US9180133B2 (en) 2015-11-10
ZA201006049B (en) 2011-05-25
ES2450592T3 (es) 2014-03-25
JP6138838B2 (ja) 2017-05-31
IL234149B (en) 2019-02-28
EP2252301A1 (en) 2010-11-24
HRP20140132T1 (hr) 2014-05-09
JP2015120711A (ja) 2015-07-02
JP5906016B2 (ja) 2016-04-20
CY1116485T1 (el) 2017-03-15
KR20110021709A (ko) 2011-03-04
TWI445537B (zh) 2014-07-21
US20140187525A1 (en) 2014-07-03
US8722653B2 (en) 2014-05-13
CA2713254A1 (en) 2009-09-06
US20090192130A1 (en) 2009-07-30
US20170246189A1 (en) 2017-08-31
KR101571400B1 (ko) 2015-11-24
NZ587439A (en) 2012-06-29
MX2010008270A (es) 2011-01-14
WO2009095418A1 (en) 2009-08-06
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
US9682088B2 (en) 2017-06-20
TW200944211A (en) 2009-11-01
IL207182A0 (en) 2010-12-30
PL2252301T3 (pl) 2014-07-31
EP2684565B1 (en) 2019-10-02
BRPI0907028A2 (pt) 2015-07-07
EP2252301B1 (en) 2013-12-11
CA2713254C (en) 2014-10-07
DK2252301T3 (en) 2014-02-17
EP2684565A1 (en) 2014-01-15
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
US20130023506A1 (en) 2013-01-24
BRPI0907028B8 (pt) 2021-05-25
JP2011510949A (ja) 2011-04-07
IL234149A0 (en) 2014-09-30
AU2009209652A1 (en) 2009-08-06
BRPI0907028A8 (pt) 2019-08-13
CA2857798A1 (en) 2009-09-06
BRPI0907028B1 (pt) 2019-09-24
US8299050B2 (en) 2012-10-30
AU2009209652B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
IL234149B (en) Use of an effective amount of 17-acetoxy-11-[4-n, n-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof for the manufacture of a medicament for treating or preventing leiomyomatosis or metastatic leiomyoma in a patient
IL200272A (en) Drugs containing progesterone for use in preventing premature birth and subsequent birth, and using this progesterone in the preparation of preparations for prevention of early onset and subsequent birth.
PL2148681T3 (pl) Selektywny modulator progesteronu w leczeniu krwawienia z macicy
IL215842A0 (en) Intrauterine system for use in medical treatment
IL219876A (en) Antibody or fragment thereof against human b7-h1, compositions comprising same and use thereof in the preparation of medicaments
IL216263A0 (en) Devices, methods and kits for forming tracts in tissue
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
ZA201100142B (en) Balloon catheter systems and methods for treating uterine disorders
EP2376136A4 (en) DRY DIAZENIUM DIOLATION PROCESS FOR THE PRODUCTION OF NITROGEN OXIDE FILTERING MEDICAL PRODUCTS
IL210754A0 (en) Devices, methods, and kits for forming tracts in tissue
ZA201204267B (en) Nestorone/ estradiol transdermal gel
PL2711371T3 (pl) Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
IL213325A (en) Use of imidazole derivatives for the preparation of selective activity against infections of the clostridium difficile bacterium or diseases resulting from the clostridium difficile bacterium
IL216582A0 (en) Composition for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof
EP2265234A4 (en) MEDICAL ASSOCIATIONS WITH VALVE AND THESE INCLUDING KITS
LT2381932T (lt) Intracervikalinė priemonė vaistams leisti vietiniu bei zoniniu mastu, gydant gimdos kaklelio piktybinį naviką
IL210755A0 (en) Devices and methods for forming tracts in tissue
IL197893A (en) Use of selective progesterone receptor modulators to prepare a drug for the treatment of chronic estrogen-dependent uterine tissue proliferation
ZA201100605B (en) Micronised progesterone pharmaceutical composition and uses thereof
IL208723A0 (en) Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
IL253853B (en) Dextromorphan or dextrorphan for use in the treatment of symptoms of hormonal changes that cause hot flashes and night sweats
ZA201108652B (en) A therapeutic combination comprising a pulmonary surfactant and a steroid
EP2564849A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR DISEASES RELATED TO PAIN IN THE HARNTRAKT
IL220422A0 (en) Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome
IL218069A (en) Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed